PubRank

Luis Sanchez-Perez

Author PubWeight™ 28.94‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011 2.64
2 Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 2009 2.56
3 A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 2004 2.39
4 Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010 2.13
5 Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005 2.04
6 Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 2009 2.02
7 Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007 1.60
8 Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011 1.54
9 Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A 2012 1.44
10 Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 2007 1.37
11 EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2013 1.22
12 Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J 2008 1.19
13 Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res 2009 1.09
14 Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother 2011 1.04
15 Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 2007 1.02
16 Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol 2005 0.96
17 Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. J Immunol Methods 2013 0.83
18 Immunotherapy with tumor vaccines for the treatment of malignant gliomas. Curr Drug Discov Technol 2012 0.78
19 Research highlights. Immunotherapy 2009 0.75
20 A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone 2010 0.75
21 369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts. Neurosurgery 2016 0.75